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Role of stem cell factor and mast cells in the progression of The progression of chronic renal failure (CRF) is char-
chronic glomerulonephritides. acterized by numerous common pathways leading to glo-
Background. Mast cells (MCs) have been implicated in the merulosclerosis (GS) and tubulointerstitial fibrosis [1].pathogenesis of atherosclerosis and tissue fibrosis. However,
The role of infiltrating inflammatory cells in the initiationthe role of MC in the development of renal fibrosis has not
and progression of these scarring processes is becomingbeen fully elucidated. Stem cell factor (SCF; the ligand for MC
c-kit receptor) is thought to attract and activate MCs. increasingly recognized [2]. A wide range of inflamma-
Methods. The intensity of MC infiltration and SCF expres- tory cells, including lymphocytes and monocytes, has
sion in renal biopsies from 56 patients with different forms of been implicated [2]. Furthermore, close correlationsprimary and secondary glomerulonephritis and five controls
have been demonstrated between the severity of thewere investigated by immunohistochemistry, using a mono-
interstitial inflammatory infiltrate and the renal progno-clonal anti-human MC tryptase antibody and a polyclonal anti-
human SCF antibody. sis [3]. Interactions are thought to take place between
Results. A large number of MCs were detected in the renal these infiltrating cells and resident glomerular and inter-
interstitium of the diseased kidneys. Immunostainable SCF was
stitial renal cells, leading to the initiation and progressiondetected in tubular as well as interstitial cells. MC infiltration
of GS and tubulointerstitial fibrosis, respectively [1, 3].was significantly higher in glomerulonephritis (16.9 10.2 cells/
field) compared with controls (2.8  2.1 cells/field, P  0.03). Mast cells (MCs) have been implicated in tissue fibro-
Similarly, immunostainable SCF was 0.6  0.3% for controls sis, atherosclerosis, as well as tissue reaction to tumors
and 3.3  2.1% in the glomerulonephritis group (P  0.02). [4, 5]. Preliminary reports suggest a role for MCs in the
MC infiltration was highly correlated with SCF expression in
pathogenesis of renal inflammation and scarring [6]. MCsdiseased kidneys (r  0.93, P  0.0001). Double immunostain
have the capacity to secrete cytokines and growth factorsshowed them to colocalize in some interstitial cells. Analysis
of MC proliferation [proliferating cell nuclear antigen (PCNA) capable of generating positive feedback loops of in-
positivity] and apoptosis (in situ end labeling of DNA) showed flammation and fibrosis [7].
these cells to be terminally differentiated. Both MCs and SCF Mast cells are bone marrow–derived hematopoieticwere correlated with interstitial fibrosis (R  0.71 for MC and
cells that share phenotypic characteristics with mono-R 0.62 for SCF, P 0.0001) and interstitial -smooth muscle
cytes/macrophages [8]. Once in the tissue, these cellsactin (R  0.69 for MC and R  0.60 for SCF P  0.0001).
Using regression analysis, the number of MC infiltration was differentiate and proliferate under the influence of the
found to be a very powerful determinant of interstitial fibrosis local microenvironment [9]. This may depend on interac-
in the glomerulonephritis group (R2  91.4%).
tions between MCs and other leukocytes as well as tissueConclusion. MCs as an infiltrating hematopoietic cell and
fibroblasts [10]. Fibroblasts are known to secrete a wideits growth factor (SCF) seem to be up-regulated in glomerulo-
nephritis, and may play a role in the development of renal range of growth factors, including stem cell factor (SCF),
fibrosis. which acts on MCs through its c-kit receptor [11].
Stem cell factor, also known as MC growth factor, steel
1 See Editorial by Eddy, p. 375 factor, or kit ligand, is essential for MC development [12]
and was shown to be a major MC agonist under both
Key words: Schistosoma nephropathy, myofibroblasts, glomeruloscle-
physiologic and pathologic conditions, leading to MCrosis, interstitial fibrosis, atherosclerosis, renal fibrosis, chronic renal
failure. chemotaxis, adhesion, activation, proliferation, and via-
bility [13].Received for publication May 26, 2000
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Table 1. Clinical data of patients and controls night incubation at 4C. For PCNA, antigen-revealing
techniques were performed in the form of microwavePatients Controls
Variable (n  56) (n  5) treatment of sections in Tuf solution (Signet, Glasgow,
Age years 29.617.3 43.112.4 UK) for 1 minute, whereas for MCT, the sections were
Serum urea mg/dL 122.190.4 28.114.1 trypsinized for 10 minutes in 37C. The following day, the
Serum creatinine mg/dL 4.94.5 1.10.3
biotinylated secondary antibody (Vector Laboratories,MAP mm Hg 108.718.5 95.86.1
Proteinuria g/24 h 1.82.4 0 Peterborough, UK) was added at a concentration of 5%
for 30 minutes followed by addition of the ABC (VectorData are meanSD. Abbreviation is MAP, mean arterial pressure.
Laboratories). Visualization of the reaction was per-
formed using 3 amino-ethyl-9-carbazole (AEC; Vector
Laboratories) as the chromogen. All steps were performed
The progression of CRF in these patients is often corre- at room temperature (RT) in a humidity chamber unless
lated with the severity of the tubulointerstitial changes otherwise specified. Antigen-revealing techniques were
[14]. Increasing evidence suggests that the processes of used with trypsin 0.1% for 20 minutes at RT for MC
GS and tubulointerstitial fibrosis share common path- tryptase. Controls included incubation of sections in the
ways, including inflammatory cell infiltration, fibroblasts/ absence of the primary antibody or with nonimmune
myofibroblasts proliferation, and excessive deposition of appropriate gamma globulins.
extracellular matrix [1]. The primary antibodies used were monoclonal anti-
With this in mind, we sought to determine the presence human MC tryptase antibody (Dako, Ely, UK) [15],
and relevance of MCs and their growth factor (SCF) to monoclonal anti-human -smooth muscle actin antibody
renal scarring in a wide range of nephropathies. We also (-SMA; Dako) [16], monoclonal anti-CD68 (PG-M1,
attempted to identify the relationship of MCs and SCF to monocyte/macrophage; Dako) [17], polyclonal rabbit
renal fibroblasts/myofibroblasts as well as tissue fibrosis. anti-human c-kit (CD117; Dako) [18], polyclonal goat
anti-human SCF antibody (Santa Cruz, Santa Cruz, CA,
USA) [19], and monoclonal antiproliferating cell nuclearMETHODS
antigen (PCNA, PC 10) clone (Dako) [20].
Patients
Double immunostainingWe retrospectively studied renal biopsy archival mate-
rial from 56 patients with mixed primary (N  18) and Double immunohistochemical staining was performed
secondary (N  38) glomerulonephritis. The secondary on paraffin sections for MC tryptase, -SMA, and CD68
glomerulonephritides included 16 patients with schisto- with SCF. This was aimed to determine the possible
somal nephropathy, 6 patients with systemic lupus ery- associations between these cells (MCs, myofibroblasts,
thematosus (SLE), 5 patients with anti-neutrophil cyto- and monocytes/macrophages) and SCF. Briefly, 4 m sec-
plasmic antibody (ANCA)-positive vasculitis, 4 with tions were dewaxed and hydrated. Sections were pro-
secondary membranous glomerulonephritis (2 of them cessed as described previously in this article for SCF. Af-
after drugs and 2 had bronchogenic carcinoma), 3 with terward, they were preincubated with blocking (horse)
poststreptococcal glomerulonephritis, 3 with amyloido- serum for 30 minutes, labeled with the antitryptase,
sis, and 1 with Alport syndrome. For control purposes, -SMA, or CD68 antibody at 37C for one hour. Sections
our study included the sections from the healthy pole of were labeled with biotinylated secondary anti-mouse [in
nephrectomy specimens (N  5, removed for hyper- a 5% phosphate-buffered saline (PBS)/normal rat serum
nephroma). The clinical characteristics of the groups solution] at 37C for 30 minutes and then incubated with
studied are given in Table 1. ABC compound for 30 minutes at 37C. 3,3 Diamino-
benzidine tetrahydrochloride (DAB) was used as the
Immunohistochemistry chromogen. Control sections were incubated with non-
Renal biopsies were fixed in 10% neutral-buffered immune normal rat serum (at a comparative protein
formalin, paraffin-embedded, sectioned at 4 m, and concentration). Positive staining was seen as a brownish
stained using a standard avidin-biotin-peroxidase com- cytoplasmic deposit. Intervening washes were performed
plex (ABC) technique. Briefly, sections were deparaffin- with 0.1% nonionic detergent in PBS.
ized and rehydrated in descending grades of alcohol. Double staining for PCNA and apoptosis was per-
Following blocking of endogenous peroxidase activity formed on MC-stained sections. This was aimed to deter-
with 3% H2O2 in methanol and nonspecific binding sites mine the fate of these cells in renal tissues.
with a protein blocker, the primary antibody was added
In situ end labeling/apoptosis stainingin the following concentrations: anti-MC tryptase (MCT)
1:150, anti-SCF 1:100, anti–c-kit (CD117) 1:50, and anti- Apoptosis was detected by the in situ end labeling
(ISEL) of fragmented DNA using a commercial Apo-proliferating cell nuclear antigen (PCNA) 1:50, with over-
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Table 3. Immunohistochemical scores for interstitial mast cellsTable 2. Histopathologic diagnoses of the studied groups
(MC) and stem cell factor (SCF) in the two studied groups
Number
Pathologic diagnosis (percent of total) Patients Controls
Marker (n  56) (n  5) P value
Mesangiocapillary glomerulonephritis (MCGN) 31 (55)
Membranous nephropathy (MN) 4 (7) MC/HPF 16.910.19 2.82.1 0.023
SCF % 3.32.1 0.60.3 0.020Mesangioproliferative glomerulonephritis (MPGN) 7 (12.5)
Focal and segmental glomerulosclerosis (FSGS) 5 (9) HPF is high power field.
Amyloidosis 3 (5.5) Data are mean  SD.
End-stage renal disease (ESRD) 6 (11)
A total of 56 patients were studied.
as previously described [22]: glomerular mesangial hy-
percellularity, GS, tubular atrophy, interstitial cellularptag kit (Intergen, Purchase, NY, USA) [21]. Briefly,
infiltration, IF, and vascular hyalinosis.sections were deparaffinized and stripped of proteins by
incubation with proteinase K (Sigma, Poole, Dorset,
Statistical analysisUK) in PBS at RT for 15 minutes. Following washing
The results are expressed as mean  SD. The signifi-in distilled water, endogenous peroxidase activity was
cance of differences between the clinical groups was de-quenched by 3% H2O2 for five minutes. After incubation
termined by Kruskall-Wallis followed by Mann-Whitneywith the equilibration buffer, the samples were incubated
U Wilcoxon Rank sum test for post hoc comparisons.with terminal deoxyribonucleotidyl transferase (TdT) in
Correlations between the different parameters were per-reaction buffer (containing digoxigenin-labeled nucleo-
tide) at 37C for 60 minutes. The reaction was terminated formed using the Spearman’s rank correlation test. Sim-
using a stop buffer. Following rinsing with PBS, the tissue ple regression analysis using a computer-based program
sections were covered with antidigoxigenin peroxidaser (SPSS) was performed. The coefficient of determination
for 30 minutes at RT, washed in PBS, stained with DAB, (R2) is expressed as a percentage. A P value of  5%
and counterstained with hematoxylin. was considered significant.
Morphometric analysis
RESULTSAll the morphologic evaluations were performed by
Clinical findingstwo of the authors (A.F. and N.B.) blinded to the experi-
mental code. A standard point-counting method was The majority (60%) of patients studied had impaired
used to quantitate Masson trichrome stain for estimation renal function (serum creatinine 1.5 mg/dL). A signifi-
of both glomerular sclerosis (GS) and interstitial fibrosis cant proportion (96%) had proteinuria (300 mg/24
(IF) and for counting the percentage of SCF positivity hours). Seventy-eight percent of the patients had a sig-
as well under a magnification of 	400 [22]. For that, nificant grade of proteinuria (greater that 1 g/24 hours).
12 consecutive nonoverlapping fields were evaluated in Hypertension, often treated, was present in 67% of pa-
quantitation of the interstitium. A total of 81	 12 points tients. Control patients had normal serum creatinine at
was evaluated in each biopsy. All available glomeruli in the time of the nephrectomy. None was known to have
the biopsy were point counted. All positively staining proteinuria or hypertension. The clinical profile of the
points falling on the grid’s cross-points were counted. patient is detailed in Table 1.
The result was expressed as the percentage of stained
points of the total number of points counted. The mean Histopathological diagnosis
score per biopsy was calculated.
This histologic evaluation and description of the glo-To quantitate the amount of MCs (tryptase 
 cells) in
merular and tubulointerstitial parameters of the renalboth glomerular and tubulointerstitial compartments, 12
biopsies are described in Table 2. Histologically, the polefields in the cortical areas of each kidney were examined
of the nephrectomy specimens used for the analysis wasat a magnification of 	400 with a Reichert microscope.
normal.All available glomeruli in the biopsy were screened for
positive cells as well. During evaluation of the interstitial Mast cell (tryptase 
 cells) expression
areas, fields containing glomerular parts were ignored.
The two methods used for the detection of MC,We confirmed the nature of MC by additional staining
namely, immunostaining for MCT and toluidine blue,of the paraffin-embedded sections with toluidine blue,
were concordant (Fig. 1). Very few MCs were detecteda well-established histologic stain to identify MCs [15].
in the interstitium of normal kidneys. In contrast, many
Semiquantitative histomorphometric analysis MCs were detected in periglomerular areas as well as in
large numbers in the renal interstitium of diseased kid-This was performed with the following parameters
evaluated according to an arbitrary score (from 0 to 
3) neys (Table 3 and Fig. 2 A, B). The distribution of MC
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Fig. 1. (A) Photomicrograph showing the immunostain for mast cell Fig. 3. (A) Photomicrograph showing immunostaining for stem cell
tryptase (MCT) in a diseased cell (	200). (B) Photomicrograph showing factor (SCF) within a glomerular parietal epithelial cell of a diseased
mast cells (MC) in the interstitium of a diseased kidney stained with kidney (	400). (B) Immunostaining for SCF within tubular cells of a
toluidine blue (	200). diseased kidney (	400).
Fig. 4. (A) Photomicrograph showing double staining (brown color)
for SCF and CD68
macrophages within an interstitial cell in a diseased
kidney (	400). (B) Double staining (brown color) for SCF and MCT
within an interstitial cell in a diseased kidney (	400).
Fig. 2. (A) Photomicrograph showing MCT
 cells in the renal intersti-
tium. (B) Periglomerular distribution of MC (	400). (C ) Distribution
of -smooth muscle actin (-SMA)
 cells in a diseased kidney (	200).
(D) CD68
 cells among interstitial infiltrates (	200).
was mainly cortical with few medullary infiltrating cells. Fig. 5. (A) Photomicrograph showing few interstitial cells stained for
C-kit in a diseased kidney (	400). (B) Photomicrograph showing anThis distribution was similar to that of -SMA–positive
interstitial cell stained for C-kit with a membrane-bound pattern ofmyofibroblasts (Fig. 2C). The intensity of the distribution
immunostaining (	400).
of MC varied, although this was always in a sporadic
rather than a clustered manner, unlike CD68-positive
macrophages that were invariably included in areas of
heavy inflammatory interstitial infiltrations (Fig. 2D). No No significant difference in the distribution pattern of SCF
was observed between different nephropathies.significant difference in the distribution pattern of MC
was observed between different nephropathies. Double There was a very highly positive correlation between
the number of MCs and the intensity of SCF immuno-immunostaining of tryptase 
 cells for PCNA and their
ISEL failed to show any proliferating or apoptotic MCs. staining in the nephropathy group (Table 4). On the
other hand, a weaker correlation was noted between
Stem cell factor expression the overall severity of interstitial inflammation and SCF
immunostaining (r  0.314, P  0.048).Stem cell factor was detectable in few normal kidneys
within the interstitial area. In diseased kidneys, SCF ex- Double immunostain showed SCF to colocalize with
both interstitial monocytes/macrophages (CD68-positivepression was located in a few glomerular parietal epithe-
lial cells (Fig. 3A). In addition, SCF immunostain was cells) as well as MCs (tryptase-positive cells; Fig. 4).
The SCF receptor (c-kit) was detected in a few intersti-detectable in the tubulointerstitium (tubular cells, fibro-
blasts, peritubular capillaries, and the renal interstitium; tial cells (Fig. 5A). The distribution of the immunostain
was very suggestive of a membrane-associated receptorFig. 3 B, C). There was significantly more immunoreactive
SCF in diseased kidneys compared with controls (Table 3). (Fig. 5B).
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Table 4. Correlation between the studied parameters Mast cells have been implicated in the pathogenesis
of fibrosis, as they are capable of releasing a wide rangeMC (interstitial) SCF (interstitial)
of fibrogenic factors and growth factors [26], includingDiagnosis r P r P
histamine, tryptase, as well as transforming growth fac-
Glomerulosclerosis 0.59 0.001 0.53 0.001
tor- (TGF-) and basic fibroblast growth factor (bFGF)Interstitial fibrosis 0.71 0.0001 0.62 0.001
-SMA 0.69 0.0001 0.60 0.001 [27]. Histamine is a potent stimulator of fibroblast prolif-
SCF 0.93 0.0001 1 eration and collagen synthesis [28]. Tryptase, on the
Abbreviations are: -SMA, -smooth muscle actin; SCF, stem cell factor. r, other hand, is chemotactic as well as mitogenic for fibro-
coefficient of correlation; P, level of significance.
blasts [29]. TGF- is thought to be one of the most potent
renal fibrogenic growth factors [30]. The proximity of
MCs and myofibroblasts in kidney sections suggests that
there are close interactions between these cells withinCorrelations between the studied parameters
the renal interstitium. MCs are likely to be key playersThere was a strong positive correlation between the
in the pathogenesis of IF as previously suggested in renalseverity of GS and both the number of interstitial MCs
allografts [24] and IgA nephropathy [25]. This is sup-and immunostainable SCF in diseased kidneys (Table 4).
ported in our study by the close correlations betweenFurthermore, both the number of interstitial MCs and the
the number of interstitial MC and the severity of IF. Thedistribution of interstitial SCF immunostain were very
power of MC to determine the severity of such a fibrosisstrongly correlated with the severity of interstitial fibrosis
exceeded that of interstitial inflammatory infiltrate as(Table 4). The number of interstitial MCs was found to
well as that of myofibroblasts. Until now the latter werebe powerful determinants of IF in diseased kidneys. This
thought to be one of the most powerful predictors of IFpredictive power exceeded that of any other parameter,
in human renal biopsies [22, 31].including the number of interstitial myofibroblasts, as
For the first time, to our knowledge, we also detectedthe coefficient of determination (R 2) for MCs was 91%,
SCF in human kidneys. While barely detectable in nor-whereas that of interstitial -SMA
 cells was only 67%.
mal kidneys, there was a marked up-regulation of itsIn addition, there was a strong correlation between the
immunostain in diseased kidneys. SCF distribution wasextent of SCF immunostaining and the degree of tubular
both cellular and interstitial. It appeared to localize inatrophy (r  0.626, P  0.0001). On the other hand,
areas of interstitial expansion and fibrosis, and was de-there was no correlation between SCF immunostain and
tectable primarily in tubular cells and in interstitial infil-proteinuria.
trating cells. Whether these cells produce SCF and attract
MCs to the interstitium remains to be determined. Of
DISCUSSION interest, some have attributed similarities between MCs
and marrow-derived monocytic cells [32]. In the intersti-Our study shows that scarred human kidneys are asso-
ciated with a significant infiltration of the interstitium tium, SCF appears to be associated with a variety of
cells. The observed association of SCF around and withinwith MCs. Using an antitryptase antibody, these have
been identified in areas of interstitial fibrosis in associa- MC confirms the role of this factor in the attraction,
activation, and proliferation of MCs [13]. MCs are knowntion with myofibroblasts. This method has been validated
by others and found to be reliable for the detection of to have cell surface receptors for this growth factor [11].
Our study identifies the presence of the SCF receptor,these cells in paraffin sections [15]. Also, the MCs were
stained by toluidine blue, which showed essentially the c-kit, in a few interstitial cells. A cell surface distribution
was suggested from the immunostaining pattern. It hassame distribution of the tryptase-positive MC. Our data
confirm previous observations of the association between previously been established that this cell surface receptor
is unique to tissue MCs [17]. The fact that there areMCs and inflammatory as well as fibrotic diseases. A
role has been attributed to these hematopoietic cells fewer cells staining for the SCF receptor (c-kit) can be
explained, as previously suggested [33], by a decrease inin tissue fibrosis, including that following experimental
myocardial ischemia [23]. In ischemic hearts as in our the number of c-kit–positive cells caused by probable
occupation of the receptor by the SCF or its down-regu-kidney sections, these cells accumulate in areas of fibrosis
and collagen deposition [23]. MCs have been associated lation and internalization after ligand-receptor interac-
tion [33]. SCF immunostain was also observed in intersti-with acute cellular rejection of human renal allografts
and the ensuing renal fibrosis [24]. They have also been tial monocytes, known to produce and release SCF [34].
Furthermore, a few myofibroblasts appeared to doubledetected in the kidneys of patients with chronic IgA
nephropathy where they seemed to influence the pro- stain for SCF, suggesting interactions between these cells
and MCs. Some tubular cells appeared to stain for SCF.gression of the disease [25]. In that study, patients with
a high number of interstitial MCs had severe interstitial Furthermore, there was a close correlation between the
severity of tubular atrophy and the immunostaining forfibrosis and progressive nephropathy [25].
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in glomerular disease: Its role in the progression or renal damage.SCF, suggesting an association. Whether atrophic or in-
Am J Kidney Dis 26:124–132, 1995
jured tubular cells produce and release SCF is unknown. 15. Walls AF, Bennett AR, McBride HM, et al: Production and
Activated tubular cells have been shown to release a wide characterization of monoclonal antibodies specific for mast cell
tryptase. Clin Exp Allergy 20:581–589, 1990range of cytokines, chemokines, and growth factors [35].
16. Skalli O, Ropraz P, Trzeciak A, et al: A monoclonal antibodyThe association of MCs, monocytes, myofibroblasts, against -smooth muscle actin: A new probe for smooth cell differ-
and SCF within human kidney biopsies suggests a very entiation. J Cell Biol 103:2787–2796, 1986
17. Falini B, Flenghi L, Pileri S, et al: PG-M1, a new monoclonalpotent fibrogenic environment. It is likely that the inter-
antibody directed against a fixative-resistant epitope on the macro-actions between these cells are facilitated by the release phage restricted form of the CD68 molecule. Am J Pathol 142:1359–
and action of SCF. However, this is most probably one 1372, 1993
18. Tsuura Y, Hiraki H, Watanabe K, et al: Preferential localizationof many growth factors released by these cells that may
of c-kit product in tissue mast cells, basal cells of skin, epithelialbe involved in these inflammatory and fibrogenic interac-
cells of breast, small cell lung carcinoma and seminoma/dysgermi-
tions within diseased kidneys. noma in human: Immunohistochemical study of formalin-fixed,
paraffin-embedded tissues. Virchows Arch 424:135–141, 1994In conclusion, we show that MCs and their associated
19. Galli SJ, Zsebo KM, Geissler EN: The kit ligand, stem cell factor.growth factor (SCF) and its receptor (c-kit) are present
Adv Immunol 55:1–96, 1991
within the interstitium of scarred human kidneys. We 20. Waseem NH, Lane PP: Monoclonal antibody analysis of the prolif-
erating cell nuclear antigen (PCNA): Structural conservation andpostulate that they play a role in the initiation and pro-
the detection of a nucleolar form. J Cell Sci 96:121–129, 1990gression of renal IF. However, confirmation of such a
21. Zhang G, Oldroyd S, Huang LH, et al: Role of apoptosis in
hypothesis and the precise mechanisms involved remain the development of tubulointerstitial fibrosis during experimental
obstructive nephropathy. Exp Nephrol 9:71–80, 2001to be determined by further studies.
22. Goumenos D, Brown CB, Shortland J, El Nahas AM: The
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